|
|
| Thérapies > Etude de marché sectorielle |
|
|
|
|
€ 160,00 |
Editeur
: |
Datamonitor |
Langue
: |
Anglais |
Date de publication : |
Avril 2005 |
Taille du document : |
30 |
Autres informations : |
Description , Table des matières |
| |
|
|
|
|
| |
|
Rechercher d'autres rapports et études à commander
Rechercher et commander ici parmi 50.000 études de marché publiées par les principaux instituts d'études internationaux
|
| Rapports privés en relation |
|
MarketWatch: Cancer
31 pages | Février 2005 |
Datamonitor's Cancer MarketWatch is a one-stop news shop for time-pressed executives.
It provides monthly insight into the key events in the cancer therapeutic area.
MarketWatch features all the |
160,00 €
|
| |
| |
MarketWatch: Cancer
31 pages | Janvier 2005 |
Datamonitor's Cancer MarketWatch is a one-stop news shop for time-pressed executives.
It provides monthly insight into the key events in the cancer therapeutic area.
MarketWatch features all the |
160,00 €
|
| |
| |
Neutraceuticals: Consumer Targeting by Age Profile
300 pages | Septembre 2000 |
Success stories such as Yakult and Red Bull clearly illustrate the potential for companies to expand sales, gain share and even create new categories in the largely slow growth food and drink market.< |
1 595,00 €
|
| |
| |
Cancer Vaccines: Measuring Market Potential
232 pages | Octobre 2004 |
This report provides an overview of the emerging market for cancer vaccines and measures their potential impact on a number of cancer markets.
Vaccine product candidates are discussed within the co |
1 200,00 €
|
| |
| |
Nutraceuticals - Targeting Consumers Aged 14 –34
146 pages | Septembre 2000 |
The 14-34 age group represents approximately 30% of the total population across the 8 countries covered in the report, and as such are a key target audience.
This group is particularly critic |
955,00 €
|
| |
| |
Commercial Insight: Cytotoxics - Generic Adversity Facing Major Cytotoxics
126 pages | Juillet 2005 |
IntroductionThere is a plethora of cytotoxics on the market but only a few dominate in terms of sales.
Yet, patents for major drugs are expected to expire in the short to mid term, and sales will d |
12 160,00 €
|
| |
| |
MarketWatch: Cancer
33 pages | Mars 2005 |
Datamonitor's Cancer MarketWatch is a one-stop news shop for time-pressed executives.
It provides monthly insight into the key events in the cancer therapeutic area.
MarketWatch features all the |
160,00 €
|
| |
| |
MarketWatch: CNS
29 pages | Octobre 2005 |
Datamonitor's CNS MarketWatch is a one-stop news shop for timepressed executives.
It provides monthly insight into the key events in the CNS industry.
The report contains the latest news, analys |
170,00 €
|
| |
| |
MarketWatch: Cancer
32 pages | Juillet 2005 |
Datamonitor's Cancer MarketWatch is a one-stop news shop for time-pressed executives.
It provides monthly insight into the key events in the cancer therapeutic area.
MarketWatch features all the |
160,00 €
|
| |
| |
Market Leaders in Oncology 2004 - Roche and Genentech Continue to Blaze a Trail
71 pages | Janvier 2005 |
IntroductionRoche continues to lead the oncology sector, recording oncology sales of $5,719m in 2003.
This sector dominance is predicted to continue between 2004 and 2010, due to Roche's ability to |
3 040,00 €
|
| |
| |
|
| |
| Autres secteurs en relation |
|
|
|
| |
|
| |
| |
| Présentation de l'étude de marché - Description & Table des matières |
|
|
|
Datamonitor's CNS MarketWatch is a one-stop news shop for timepressed executives. It provides monthly insight into the key events in the CNS industry. The report contains the latest news, analysis and opinion, covering all the month's major issues and events in R&D, regulatory and licensing in the
CNS industry.
|
|
In this month’s MarketWatch…
This month's highlights
Page 2 - Key Announcements
Page 2 - CNS News Round-Up
Neurology
Page 4 - Headlines
Page 4 - Alzheimer's Disease Update
Page 6 - Multiple Sclerosis Update
Page 8 - Parkinson's Disease Update
Psychiatry
Page 10 - Headlines
Page 10 - Depression Update
Page 12 - Behavioral Update
Pain
Page 14 - Opinion
Page 16 - Headlines
Page 16 - R&D Update
Page 18 - Regulatory Update
Feature Analysis
Page 20 - Testing times for Tysabri
Company Spotlight
Page 22 - Bristol-Myers Squibb Company
Further Reading
Page 28
Index
Page 29 - Pharma companies
Page 29 - Biotech companies
Page 30 - Key Drugs
|
|
|
PPLSEN
|
|
|
|
|
